Predicting Treatment Outcomes in Chronic HCV Genotype 3a Patients
Author Information
Author(s): Isabelle Moreau, John Levis, Orla Crosbie, Elizabeth Kenny-Walsh, Liam J Fanning
Primary Institution: Cork University Hospital, Cork, Ireland
Hypothesis
Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon-based anti-viral therapy.
Conclusion
Lower quasispecies complexity and diversity at baseline are associated with better treatment outcomes in chronic HCV genotype 3a patients.
Supporting Evidence
- Quasispecies complexity and diversity are lower in the sustained virological responders (SVR) group.
- Genetic heterogeneity at baseline can predict treatment outcomes.
- Temporal changes in quasispecies complexity were observed during treatment.
Takeaway
This study found that patients with simpler virus types before treatment are more likely to get better after taking medicine for hepatitis C.
Methodology
The study analyzed serum samples from 10 patients, assessing quasispecies complexity and diversity before and during treatment with pegylated interferon and ribavirin.
Potential Biases
Potential biases may arise from the retrospective design and the limited number of patients.
Limitations
The study had a small sample size and was retrospective in nature.
Participant Demographics
10 patients (7 females, 3 males) with a mean age of 41 ± 9 years.
Statistical Information
P-Value
0.019
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website